Biothera Pharmaceuticals, Inc. is advancing Imprime PGG, a unique cancer immunotherapy, through Phase 2 clinical trials in multiple cancer indications. While cancers can actively avoid detection by the immune system, Imprime PGG works like an immunological “ignition switch” to activate a host of anti-tumor immune system responses. These robust, coordinated responses can enhance the therapeutic efficacy of tumor-targeting, anti-angiogenic and immune checkpoint inhibitor antibodies.
Imprime PGG is the first systemically administered Pathogen Associated Molecular Patterning (PAMP) drug. Studies in over 400 patients have demonstrated clinical proof of concept and robust safety for Imprime PGG in combination with anti-cancer antibodies.
The Company is developing Imprime PGG in Phase 2 combination trials with checkpoint inhibitors in melanoma, triple negative breast cancer, non-small cell lung cancer and head and neck cancer. Significant milestones, including response, safety and biomarker data, are expected through 2017-18.